Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients

Phase II Trial of Thalidomide (Thalidomide Pharmion) in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)

NCT00373646•Medical University of Vienna

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate Thalidomide for treatment of disseminated MALT Lymphoma or at relapse following helicobacter pylori (HP) - eradication or chemotherapy or radiation.

Detailed Description

The objectives of this study are to evaluate the effectivity and the safety of thalidomide in patients with disseminated MALT lymphoma or at relapse following HP-eradication, or chemotherapy or radiation. It is a phase II prospective single arm study with a target sample size of 16 patients. Thalidomide is given orally at an initial dose of 100 mg for a maximum duration of 6 months.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with histologically confirmed MALT lymphoma with measurable disease (Stage I-IV)
•With first or greater relapse after HP-eradication, radiation or chemotherapy
•Age \> 18
•Must be able to tolerate therapy and have adequate cardiac, renal and hepatic function
•ECOG status \_\< 2
•Must be capable of understanding the purpose of the study and have given written informed consent

Locations (1)

Department of Internal Medicine I

Vienna, Austria

Key Dates

Start Date

June 1, 2006

Primary Completion Date

January 1, 2009

Completion Date

January 1, 2009

Last Updated

June 18, 2009

Enrollment

ACTUAL participants

Conditions

MALT Lymphoma

Interventions

Thalidomide, Pharmion

DRUG

Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma

NCT06228963

MALT Lymphoma of StomachHelicobacter Pylori Infection

View study

ACTIVE_NOT_RECRUITINGPHASE2

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

NCT01808599

MALT Lymphoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 18, 2009Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions